Dr. Zahra Pakbaz, MD

Dr. Pakbaz practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Pakbaz's NPI, 1942463377, was assigned on July 7, 2008. Dr. Pakbaz graduated from Tehran University of Medical Sciences School of Medicine in 1999. Dr. Pakbaz holds California license 117499.

Dr. Pakbaz's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Pakbaz's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. Dr. Pakbaz is also affiliated with Riverside University Health System - Medical Center. The medical group on file is UCI Health Physicians. Dmand AI also links Dr. Pakbaz to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pakbaz practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Pakbaz's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Pakbaz is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Pakbaz's licenses on file in 2 states: California and Maryland.

Dmand AI lists chronic anemia, chronic embolism thrombosis, deep vein thrombosis (DVT), immune deficiency disease, neutropenia, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Pakbaz treats.

CMS data shows 659 Medicare services from Dr. Pakbaz across 6 procedure codes in 2024, for 166 Medicare patients. Medicare paid $46,857 for them.

CMS counts 166 Medicare patients who saw Dr. Pakbaz in 2024. The largest group is 65 to 74, with 61 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 49% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pakbaz's median patient age at 60, with 61% women.

In 2024, Dr. Pakbaz wrote 328 Medicare Part D claims for 39 patients. 60% of them were for generic drugs. CMS names the drug for 208 of them, across 10 drugs with 11 or more claims each, at $1,163,793 in total drug cost. In 2023, CMS named 132 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Pakbaz for performance year 2024, reported through an alternative payment model (APM). Dr. Pakbaz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pakbaz as offering telehealth.

Dmand AI links 29 papers to Dr. Pakbaz, published from 2004 to 2025. 2023 was the busiest year, with 4. The most frequent topics are Anemia, Sickle Cell, Iron and Thalassemia. Dr. Pakbaz has published most often in J Community Hosp Intern Med Perspect. Dr. Pakbaz's most frequent co-authors are Paul R. Harmatz, MD, Thomas D. Coates, MD and Elliott P. Vichinsky, MD.

Dmand AI links Dr. Pakbaz to 5 clinical trials, 4 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Hemolysis, Sickle Cell Trait and alpha-Thalassemia. Forma Therapeutics, Inc. sponsors the most, 2.

CMS Open Payments shows 141 general payments to Dr. Pakbaz from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 54% of the total. Novartis Pharmaceuticals Corporation paid the most, $50,994.

Dr. Pakbaz graduated from Tehran University of Medical Sciences School of Medicine in 1999.

Dr. Pakbaz is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.